当前位置: X-MOL首页全球导师 国内导师 › 吴宝剑

个人简介

分别于2004年、2007年和2011年获复旦大学药学学士、复旦大学药剂学硕士及美国休斯敦大学(University of Houston)药剂学博士学位。博士毕业后在美国贝勒医学院(Baylor College of Medicine)进行博士后研究。2012年9月回国,在暨南大学药学院从事教学与科研工作。

研究领域

药物新剂型、代谢及药物动力学。

近期论文

查看导师最新文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

1. Zhang X, Dong D, Wang H, Ma Z, Wang Y, Wu B*. (2015). Stable Knock-down of Efflux Transporters Leads to Reduced Glucuronidation in UGT1A1-Overexpressing HeLa Cells: The Evidence for Glucuronidation-Transport Interplay. Mol Pharm. 12(4):1268-78. 2. Li W, Sun H, Zhang X, Wang H, Wu B*. (2015). Efflux transport of chrysin and apigenin sulfates in HEK293 cells overexpressing SULT1A3: The role of multidrug resistance-associated protein 4 (MRP4/ABCC4). Biochem Pharmacol. 98(1):203-14. 3. Quan E, Wang H, Dong D, Zhang X, Wu B*. (2015). Characterization of Chrysin Glucuronidation in UGT1A1-Overexpressing HeLa Cells: Elucidating the Transporters Responsible for Efflux of Glucuronide. Drug Metab Dispos. 43(4):433-43. 4. Sun H, Wang X, Zhou X, Lu D, Ma Z, Wu B*. (2015). Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) Controls Efflux Transport of Hesperetin Sulfates in Sulfotransferase 1A3-Overexpressing Human Embryonic Kidney 293 Cells. Drug Metab Dispos.43(10):1430-40. 5. Wu Z, Wang S, Peng X, Lu C, Ye X, Wu B*. (2015). Altered Cisatracurium Pharmacokinetics and Pharmacodynamics in Patients with Congenital Heart Defects. Drug Metab Dispos. pii: dmd.115.067405. 6. Zhang X, Chen G, Zhang T, Ma Z, Wu B*. (2014). Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigation. Int J Nanomedicine. 9:5503-14. 7. Zhang X, Zhang T, Ye Y, Chen H, Sun H, Zhou X, Ma Z, Wu B*. (2015). Phospholipid-stabilized mesoporous carbon nanospheres as versatile carriers for systemic delivery of amphiphobic SNX-2112 (a Hsp90 inhibitor) with enhanced antitumor effect. Eur J Pharm Biopharm. 94:30-41. 8. Li W, Zhang T, Ye Y, Zhang X, Wu B*. (2015). Enhanced bioavailability of tripterine through lipid nanoparticles using broccoli-derived lipids as a carrier material. Int J Pharm. 495(2):948-955. 9. Zhou X, Zhang X*, Ye Y, Zhang T, Wang H, Ma Z, Wu B*. (2014). Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption. Int J Pharm. 479(2):391-398. 10. Zhang X, Zhang T, Zhou X, Liu H, Sun H, Ma Z, Wu B*. (2014). Enhancement of oral bioavailability of tripterine through lipid nanospheres: preparation, characterization, and absorption evaluation. J Pharm Sci. 103(6):1711-9. 11. Sun H, Wu Z, Wu B*. (2015). Warfarin is an Effective Modifier of Multiple UDP-glucuronosyltransferase (UGT) Enzymes: Evaluation of its Potential to Alter the Pharmacokinetics of Zidovudine. J Pharm Sci. 104(1):244-56. 12. Zhang X, Wang H, Zhang T, Zhou X, Wu B*. (2014). Exploring the potential of self-assembled mixed micelles in enhancing the stability and oral bioavailability of an acid-labile drug. Eur J Pharm Sci. 62:301-8. 13. Sun H, Wang H, Zhang T, Zhang X, Wu B*. (2014). Glucuronidation of Capsaicin by Liver Microsomes and Expressed UGT Enzymes: Reaction Kinetics, Contribution of Individual Enzymes and Marked Species Differences. Expert Opin Drug Metab Toxicol. 10(10):1325-36. 14. Liu H, Wu Z, Ma Z, Wu B*. (2014). Glucuronidation of macelignan by human liver microsomes and expressed UGT enzymes: identification of UGT1A1 and 2B7 as the main contributing enzymes. Biopharm Drug Dispos. 35(9):513-24. 15. Liu H, Sun H, Lu D, Zhang Y, Zhang X, Ma Z, Wu B*. (2014). Identification of glucuronidation and biliary excretion as the main mechanisms for gossypol clearance: in vivo and in vitro evidence. Xenobiotica. 44(8):696-707.

推荐链接
down
wechat
bug